A comparison of intranasal dexmedetomidine versus placebo in attenuation of hemodynamic responses to laryngoscopy and intubation

Not yet recruiting

• Conditions: Neoplasms,

• Registration Number: CTRI/2022/07/044460
• Lead Sponsor: Kidwai memorial institute of oncology

Brief Summary

Dexmedetomidine  is a highly selective short acting alpha 2 agonist. It can provide sedative, analgesic, anxioytic effects with minimal respiratory depression. Several studies also suggest efficacy in blunting hemodynamic  responses to laryngoscopy and intubation.  Since intravenous  use has been associated with several cases of sudden cardiac arrest and delayed post operative  recovery, we use intranasal route for our study which also is said to have good patient acceptance.  We intend to study the attenuation of hemodynamic responses to laryngoscopy and intubation following preoperative intranasal administration  of dexmedetomidine  45 minutes prior to laryngoscopy and intubation when given at a dose of 0.5 micrograms per kg. Additionally we also intend to study preoperative  anxiolysis and sedative properties of dexmedetomidine  when given intranasal. This shall be compared against intranasal administration of saline 45 minutes prior to laryngoscopy  and intubation.  The study shall be done in a randomized  double blinded placebo controlled manner. Statistical  tests  for significance shall be performed  after obtaining  the data.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2022-07-28
• Study Start: 2022-07-31

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 166

Inclusion Criteria

Patients aged between 18 to 65 years belonging to ASA status 1 ad 2 with BMI between 18 -25 kgm2 undergoing surgery under general anesthesia.

Exclusion Criteria

• Patient refusal.
• Patient with known nasal pathology.
• History of allergy to study drug or other anesthetic agents.patient with history ischemic heart disease, cerebrovascular accident, or cardiovascular disease.
• Patient with second or third degree heart blocks.
• Patients on long term sedatives or anxiolytics.
• Patients on Anti hypertensive like clonidine, beta blockers, alpha methyl dopa, alpha adrenergic agonists.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Hemodynamic responses to laryngoscopy and intubation	60 minutes

Secondary Outcome Measures

Name	Time	Method
Sedation, anxioysis	45 minutes

Trial Locations

Locations (1)

Kidwai memorial institute of oncology; 🇮🇳 Bangalore, KARNATAKA, India

Kidwai memorial institute of oncology

🇮🇳Bangalore, KARNATAKA, India

Dr Arya Vishwanath

Principal investigator

09620301823

aryavishwan@gmail.com